ARTV FY2025 EPS Estimate Reduced by Cantor Fitzgerald

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for Artiva Biotherapeutics in a note issued to investors on Thursday, August 7th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings of ($3.22) per share for the year, down from their previous estimate of ($3.04). The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share. Cantor Fitzgerald also issued estimates for Artiva Biotherapeutics’ FY2026 earnings at ($2.17) EPS.

Several other research analysts also recently issued reports on the stock. HC Wainwright upgraded shares of Artiva Biotherapeutics to a “buy” rating and set a $12.00 price target for the company in a report on Wednesday, June 11th. Needham & Company LLC decreased their price target on Artiva Biotherapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, May 15th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Artiva Biotherapeutics currently has an average rating of “Buy” and an average target price of $17.80.

Artiva Biotherapeutics Stock Performance

NASDAQ ARTV opened at $2.56 on Monday. The business has a fifty day moving average price of $2.20 and a two-hundred day moving average price of $2.94. Artiva Biotherapeutics has a fifty-two week low of $1.47 and a fifty-two week high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Wednesday, August 6th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.03).

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ARTV. Geode Capital Management LLC lifted its position in Artiva Biotherapeutics by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 315,758 shares of the company’s stock valued at $3,184,000 after acquiring an additional 6,828 shares in the last quarter. Northern Trust Corp lifted its position in shares of Artiva Biotherapeutics by 3.8% during the 4th quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock worth $1,180,000 after buying an additional 4,335 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Artiva Biotherapeutics by 26.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company’s stock worth $165,000 after purchasing an additional 11,355 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Artiva Biotherapeutics during the 1st quarter worth approximately $144,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Artiva Biotherapeutics by 250.7% during the 4th quarter. JPMorgan Chase & Co. now owns 37,619 shares of the company’s stock worth $379,000 after purchasing an additional 26,893 shares during the last quarter.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.